FemCerv®: Well-designed technology that can minimize patient discomfort 2023, Media / By lsc-webmaster
US biomedical company launches intrauterine device for tubal evaluation 2023, Media / By lsc-webmaster
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement 2022, Media / By lsc-webmaster
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs 2022, Media / By lsc-webmaster
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control 2022, Media / By lsc-webmaster
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team 2022, Media / By lsc-webmaster
Tech Companies Working On Contraception Face A New Landscape After Roe 2022, Media / By lsc-webmaster
